Innoviva (INVA) Total Non-Current Liabilities (2013 - 2026)
Innoviva posted quarterly Total Non-Current Liabilities of -$919000.0 for Q1 2026, up 98.51% year-on-year from -$462941.6 in Q1 2025, and little changed on a QoQ basis from -$919000.0 in Q4 2025.
Innoviva (INVA) has 14 years of Total Non-Current Liabilities data on file, last reported at -$919000.0 in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 98.51% year-over-year to -$919000.0; the trailing twelve-month figure through Mar 2026 stood at -$919000.0 (up 98.51% YoY), and the FY2025 full-year result was -$919000.0, up 98.27% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at -$919000.0, roughly flat from -$919000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $103.3 million in Q3 2023 and bottomed at -$69.9 million in Q1 2024.
- The 5-year median for Total Non-Current Liabilities is -$919000.0 (2025), against an average of -$5.4 million.
- The widest annual swing landed in 2022, when Total Non-Current Liabilities surged 20050.0%; it then slumped 151.35% in 2024.
- A 5-year view of Total Non-Current Liabilities shows it stood at $40.3 million in 2022, then surged by 156.24% to $103.3 million in 2023, then plunged by 151.35% to -$53.0 million in 2024, then soared by 98.27% to -$919000.0 in 2025, then changed by 0.0% to -$919000.0 in 2026.
- The last three Total Non-Current Liabilities figures came in at -$919000.0 (Q1 2026), -$919000.0 (Q4 2025), and $45.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | -919,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -919,000.00 |
| Dec 31, 2025 | -919,000.00 |
| Sep 30, 2025 | 45.15 Mn |
| Jun 30, 2025 | -55.05 Mn |
| Mar 31, 2025 | -61.81 Mn |
| Dec 31, 2024 | -53.03 Mn |
| Sep 30, 2024 | 31.01 Mn |
| Jun 30, 2024 | -69.27 Mn |
| Mar 31, 2024 | -69.89 Mn |
| Dec 31, 2023 | 103.26 Mn |
| Sep 30, 2023 | 103.26 Mn |
| Jun 30, 2023 | -67.88 Mn |
| Mar 31, 2023 | -66.03 Mn |
| Dec 31, 2022 | 40.30 Mn |
| Sep 30, 2022 | 40.30 Mn |
| Dec 31, 2021 | 200,000.00 |
| Sep 30, 2021 | 13.66 Mn |
| Jun 30, 2021 | 395.36 Mn |
| Mar 31, 2021 | 391.53 Mn |
| Dec 31, 2020 | 391.63 Mn |
| Sep 30, 2020 | 13.99 Mn |
| Jun 30, 2020 | 386.64 Mn |
| Mar 31, 2020 | 381.95 Mn |
| Dec 31, 2019 | 382.49 Mn |
| Sep 30, 2019 | 391.97 Mn |
| Jun 30, 2019 | 395.31 Mn |
| Mar 31, 2019 | 389.79 Mn |
| Dec 31, 2018 | 388.56 Mn |
| Sep 30, 2018 | 385.30 Mn |
| Jun 30, 2018 | 493.30 Mn |
| Mar 31, 2018 | 488.66 Mn |
| Dec 31, 2017 | 609.10 Mn |
| Sep 30, 2017 | 612.88 Mn |
| Jun 30, 2017 | 667.59 Mn |
| Mar 31, 2017 | 724.79 Mn |
| Dec 31, 2016 | 730.60 Mn |
| Sep 30, 2016 | 736.81 Mn |
| Jun 30, 2016 | 739.57 Mn |
| Mar 31, 2016 | 748.01 Mn |
| Dec 31, 2015 | 749.72 Mn |
| Sep 30, 2015 | 758.78 Mn |
| Jun 30, 2015 | 754.33 Mn |
| Mar 31, 2015 | 746.90 Mn |
| Dec 31, 2014 | 743.18 Mn |
| Sep 30, 2014 | 745.32 Mn |
| Jun 30, 2014 | 791.84 Mn |
| Dec 31, 2013 | 382.13 Mn |